Mengshi Hu

发表

Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.

M. Shen, Zhuang Yang, Ming-hai Tang, 2019, European journal of medicinal chemistry.

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms

T. Yang, Zhuang Yang, Ming-hai Tang, 2022, Blood Cancer Journal.

Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib

Dingguo Xu, Mengshi Hu, Mingsong Shi, 2022, Computational and structural biotechnology journal.

The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin

T. Yang, F. Wang, Heying Pei, 2018, The Journal of Biological Chemistry.

Discovery of Potent and Orally Effective Dual JAK2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.

Mingli Xiang, Zhuang Yang, Ming-hai Tang, 2019, Journal of medicinal chemistry.

Discovery of novel β-carboline/acylhydrazone hybrids as potent antitumor agents and overcome drug resistance.

Zhuang Yang, Ming-hai Tang, Yong Li, 2018, European journal of medicinal chemistry.

Correction to "Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms".

Mingli Xiang, Zhuang Yang, Ming-hai Tang, 2020, Journal of medicinal chemistry.

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors.

T. Yang, Zhuang Yang, Ming-hai Tang, 2022, Bioorganic chemistry.

A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids

Y. Liu, Mengshi Hu, Peng Bai, 2021, Drug delivery.

N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.

Mingli Xiang, Zhuang Yang, Ming-hai Tang, 2020, Journal of medicinal chemistry.